(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast ...

AVE has made a breakthrough with a phase III insomnia trial for its soft gel cannabidiol to manage sleeplessness. ... Read ...

Sponsored reels, algorithmic recommendations, and predatory marketplace listings routinely flood digital feeds, promising ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...

Researchers from University of Arizona present a new therapeutic target to shield nerve cells from the damage of ALS.

New research offers fresh hope to patients with colorectal cancer, as advances in liquid biomarker technologies are ...

Using CHARLS data from 2011 to 2020, researchers found that sleep duration and self-reported sleep quality were associated ...

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International ...